A study protocol to assess the feasibility of conducting an evaluation trial of the ADVANCE integrated intervention to address both substance use and intimate partner abuse perpetration to men in substance use treatment.
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
04
2019
accepted:
28
02
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
20
5
2020
Statut:
epublish
Résumé
Strong evidence exists that substance use is a contributory risk factor for intimate partner abuse (IPA) perpetration. Men in substance use treatment are more likely to perpetrate IPA than men from the general population. Despite this, referral pathways are lacking for this group. This trial will assess the feasibility of conducting an evaluation trial of a tailored integrated intervention to address substance use and IPA perpetration to men in substance use treatment. ADVANCE is a multicentre, parallel-group individually randomised controlled feasibility trial, with a nested formative evaluation, comparing an integrated intervention to reduce IPA + substance use treatment as usual (TAU) to TAU only. One hundred and eight men who have perpetrated IPA in the past 12 months from community substance use treatment in London, the West Midlands, and the South West will be recruited. ADVANCE is a manualised intervention comprising 2-4 individual sessions (2 compulsory) with a keyworker to set goals, develop a personal safety plan and increase motivation and readiness, followed by a 12-session weekly group intervention delivered in substance use services. Men will be randomly allocated (ratio 1:1) to receive the ADVANCE intervention + TAU or TAU only. Men's female (ex) partners will be invited to provide outcome data and offered support from integrated safety services (ISS). Regular case management meetings between substance use and ISS will manage risk. Outcome measures will be obtained at the end of the intervention (approximately 4 months post-randomisation) for all male and female participants. The main objective of this feasibility trial is to estimate parameters required for planning a definitive trial including rates of consent, recruitment, and follow-up by site and group allocation. Nested formative evaluation including focus groups and in-depth interviews will explore the intervention's acceptability to participants, group facilitators, keyworkers and ISS workers. Secondary outcomes include substance use, IPA, mental health, self-management, health and social care service use, criminal justice contacts, and quality of life. Findings from this feasibility trial will inform the design of a multicentre randomised controlled trial evaluating the efficacy and cost-effectiveness of the ADVANCE intervention for reducing IPA and improving the well-being of female (ex)partners. ISRCTN79435190.
Sections du résumé
BACKGROUND
BACKGROUND
Strong evidence exists that substance use is a contributory risk factor for intimate partner abuse (IPA) perpetration. Men in substance use treatment are more likely to perpetrate IPA than men from the general population. Despite this, referral pathways are lacking for this group. This trial will assess the feasibility of conducting an evaluation trial of a tailored integrated intervention to address substance use and IPA perpetration to men in substance use treatment.
METHODS/DESIGN
METHODS
ADVANCE is a multicentre, parallel-group individually randomised controlled feasibility trial, with a nested formative evaluation, comparing an integrated intervention to reduce IPA + substance use treatment as usual (TAU) to TAU only. One hundred and eight men who have perpetrated IPA in the past 12 months from community substance use treatment in London, the West Midlands, and the South West will be recruited. ADVANCE is a manualised intervention comprising 2-4 individual sessions (2 compulsory) with a keyworker to set goals, develop a personal safety plan and increase motivation and readiness, followed by a 12-session weekly group intervention delivered in substance use services. Men will be randomly allocated (ratio 1:1) to receive the ADVANCE intervention + TAU or TAU only. Men's female (ex) partners will be invited to provide outcome data and offered support from integrated safety services (ISS). Regular case management meetings between substance use and ISS will manage risk. Outcome measures will be obtained at the end of the intervention (approximately 4 months post-randomisation) for all male and female participants. The main objective of this feasibility trial is to estimate parameters required for planning a definitive trial including rates of consent, recruitment, and follow-up by site and group allocation. Nested formative evaluation including focus groups and in-depth interviews will explore the intervention's acceptability to participants, group facilitators, keyworkers and ISS workers. Secondary outcomes include substance use, IPA, mental health, self-management, health and social care service use, criminal justice contacts, and quality of life.
DISCUSSION
CONCLUSIONS
Findings from this feasibility trial will inform the design of a multicentre randomised controlled trial evaluating the efficacy and cost-effectiveness of the ADVANCE intervention for reducing IPA and improving the well-being of female (ex)partners.
TRIAL REGISTRATION
BACKGROUND
ISRCTN79435190.
Identifiants
pubmed: 32426156
doi: 10.1186/s40814-020-00580-7
pii: 580
pmc: PMC7212681
doi:
Types de publication
Journal Article
Langues
eng
Pagination
62Subventions
Organisme : Department of Health
ID : RP-PG-1214-20009
Pays : United Kingdom
Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Fam Violence. 1995;10(2):203-21
pubmed: 12295368
J Interpers Violence. 2011 May;26(8):1503-23
pubmed: 20522883
J Gen Intern Med. 2016 Oct;31(10):1206-11
pubmed: 27170304
J Subst Abuse Treat. 2003 Apr;24(3):279-83
pubmed: 12810149
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Crim Behav Ment Health. 2015 Dec 10;25(4):239-57
pubmed: 25939654
Int J Drug Policy. 2016 Oct;36:130-40
pubmed: 27107548
Crim Behav Ment Health. 2012 Feb;22(1):14-28
pubmed: 21823184
Eur Addict Res. 2005;11(1):22-31
pubmed: 15608468
Int J Drug Policy. 2019 Mar;65:8-23
pubmed: 30580114
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
J Interpers Violence. 2019 Oct 3;:886260519879259
pubmed: 31578902
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Subst Abuse Treat. 2014 Apr;46(4):532-9
pubmed: 24365101
Qual Life Res. 2012 Feb;21(1):167-76
pubmed: 21598064
Trauma Violence Abuse. 2018 Jul 30;:1524838018791268
pubmed: 30060720
J Acquir Immune Defic Syndr. 2007 Nov 1;46 Suppl 2:S101-9
pubmed: 18089979
Clin Psychol Rev. 2008 Oct;28(7):1222-34
pubmed: 18550239
Clin Psychol Rev. 2008 Feb;28(2):247-74
pubmed: 17604891
J Interpers Violence. 2020 May;35(9-10):1958-1981
pubmed: 29294698
J Nerv Ment Dis. 1980 Jan;168(1):26-33
pubmed: 7351540
Subst Abuse Treat Prev Policy. 2012 Sep 07;7:37
pubmed: 22958624
Bull World Health Organ. 2006 Sep;84(9):739-44
pubmed: 17128344
J Consult Clin Psychol. 2004 Apr;72(2):202-17
pubmed: 15065955
J Interpers Violence. 2016 Oct;31(17):2867-88
pubmed: 25900914
J Pers. 2004 Apr;72(2):271-324
pubmed: 15016066
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Violence Against Women. 2017 Apr;23(5):584-602
pubmed: 27178564
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Br J Psychiatry. 2003 Sep;183:228-32
pubmed: 12948996
Psychol Addict Behav. 2012 Jun;26(2):236-45
pubmed: 21823768
Acad Pediatr. 2009 May-Jun;9(3):131-2
pubmed: 19450768
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Trauma Violence Abuse. 2019 Nov 11;:1524838019882357
pubmed: 31711372
Drug Alcohol Depend. 2008 Nov 1;98(1-2):35-44
pubmed: 18554825
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Trauma Violence Abuse. 2020 Jan;21(1):123-137
pubmed: 29333972
Clin Psychol Psychother. 2010 May-Jun;17(3):231-9
pubmed: 20013760
Ethics Behav. 2013;23(6):477-488
pubmed: 25892900
J Clin Epidemiol. 2012 Mar;65(3):301-8
pubmed: 22169081
Addiction. 2008 Sep;103(9):1450-60
pubmed: 18783500
Drug Alcohol Rev. 2017 Jan;36(1):34-51
pubmed: 27709693
Drug Alcohol Rev. 2017 Jan;36(1):7-9
pubmed: 27305859
Clin Psychol Rev. 2011 Nov;31(7):1145-55
pubmed: 21851805
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941